Overview
Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants
Status:
Completed
Completed
Trial end date:
2013-07-01
2013-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Duke UniversityCollaborator:
Lantheus Medical Imaging
Criteria
Inclusion Criteria:- healthy male or female subjects between 18-45 years of age
Exclusion Criteria:
- Pregnant and lactating females
- known renal impairment
- allergy to gadolinium-based contrast
- metallic implanted devices
- claustrophobia.